181 related articles for article (PubMed ID: 38057321)
21. Characterization of the androgen-regulated prostate-specific T cell receptor gamma-chain alternate reading frame protein (TARP) promoter.
Cheng WS; Giandomenico V; Pastan I; Essand M
Endocrinology; 2003 Aug; 144(8):3433-40. PubMed ID: 12865322
[TBL] [Abstract][Full Text] [Related]
22. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression.
Zhang J; Gao N; Kasper S; Reid K; Nelson C; Matusik RJ
Endocrinology; 2004 Jan; 145(1):134-48. PubMed ID: 14500578
[TBL] [Abstract][Full Text] [Related]
23. Identification of open chromosomal regions and key genes in prostate cancer via integrated analysis of DNase‑seq and RNA‑seq data.
Wei X; Yu L; Jin X; Song L; Lv Y; Han Y
Mol Med Rep; 2018 Aug; 18(2):2245-2252. PubMed ID: 29956775
[TBL] [Abstract][Full Text] [Related]
24. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy.
Uchida A; O'Keefe DS; Bacich DJ; Molloy PL; Heston WD
Urology; 2001 Aug; 58(2 Suppl 1):132-9. PubMed ID: 11502468
[TBL] [Abstract][Full Text] [Related]
25. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter.
Cleutjens KB; van der Korput HA; van Eekelen CC; van Rooij HC; Faber PW; Trapman J
Mol Endocrinol; 1997 Feb; 11(2):148-61. PubMed ID: 9013762
[TBL] [Abstract][Full Text] [Related]
26. Enhancer release and retargeting activates disease-susceptibility genes.
Oh S; Shao J; Mitra J; Xiong F; D'Antonio M; Wang R; Garcia-Bassets I; Ma Q; Zhu X; Lee JH; Nair SJ; Yang F; Ohgi K; Frazer KA; Zhang ZD; Li W; Rosenfeld MG
Nature; 2021 Jul; 595(7869):735-740. PubMed ID: 34040254
[TBL] [Abstract][Full Text] [Related]
27. Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.
Hua JT; Ahmed M; Guo H; Zhang Y; Chen S; Soares F; Lu J; Zhou S; Wang M; Li H; Larson NB; McDonnell SK; Patel PS; Liang Y; Yao CQ; van der Kwast T; Lupien M; Feng FY; Zoubeidi A; Tsao MS; Thibodeau SN; Boutros PC; He HH
Cell; 2018 Jul; 174(3):564-575.e18. PubMed ID: 30033362
[TBL] [Abstract][Full Text] [Related]
28. CTCF-Mediated Enhancer-Promoter Interaction Is a Critical Regulator of Cell-to-Cell Variation of Gene Expression.
Ren G; Jin W; Cui K; Rodrigez J; Hu G; Zhang Z; Larson DR; Zhao K
Mol Cell; 2017 Sep; 67(6):1049-1058.e6. PubMed ID: 28938092
[TBL] [Abstract][Full Text] [Related]
29. Spatial enhancer clustering and regulation of enhancer-proximal genes by cohesin.
Ing-Simmons E; Seitan VC; Faure AJ; Flicek P; Carroll T; Dekker J; Fisher AG; Lenhard B; Merkenschlager M
Genome Res; 2015 Apr; 25(4):504-13. PubMed ID: 25677180
[TBL] [Abstract][Full Text] [Related]
30. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
[TBL] [Abstract][Full Text] [Related]
31. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer.
Perez-Stable CM; Pozas A; Roos BA
Mol Cell Endocrinol; 2000 Sep; 167(1-2):43-53. PubMed ID: 11000519
[TBL] [Abstract][Full Text] [Related]
32. A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome.
Rhie SK; Perez AA; Lay FD; Schreiner S; Shi J; Polin J; Farnham PJ
Nat Commun; 2019 Sep; 10(1):4154. PubMed ID: 31515496
[TBL] [Abstract][Full Text] [Related]
33. [Serial deletions of tandem reverse CTCF sites reveal balanced
Wang L; Li JH; Huang HY; Wu Q
Yi Chuan; 2021 Aug; 43(8):775-791. PubMed ID: 34413017
[TBL] [Abstract][Full Text] [Related]
34. YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
Weintraub AS; Li CH; Zamudio AV; Sigova AA; Hannett NM; Day DS; Abraham BJ; Cohen MA; Nabet B; Buckley DL; Guo YE; Hnisz D; Jaenisch R; Bradner JE; Gray NS; Young RA
Cell; 2017 Dec; 171(7):1573-1588.e28. PubMed ID: 29224777
[TBL] [Abstract][Full Text] [Related]
35. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
36. The LDB1 Complex Co-opts CTCF for Erythroid Lineage-Specific Long-Range Enhancer Interactions.
Lee J; Krivega I; Dale RK; Dean A
Cell Rep; 2017 Jun; 19(12):2490-2502. PubMed ID: 28636938
[TBL] [Abstract][Full Text] [Related]
37. HiC-DC+ enables systematic 3D interaction calls and differential analysis for Hi-C and HiChIP.
Sahin M; Wong W; Zhan Y; Van Deynze K; Koche R; Leslie CS
Nat Commun; 2021 Jun; 12(1):3366. PubMed ID: 34099725
[TBL] [Abstract][Full Text] [Related]
38. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system.
Yoshimura I; Ikegami S; Suzuki S; Tadakuma T; Hayakawa M
J Urol; 2002 Dec; 168(6):2659-64. PubMed ID: 12442005
[TBL] [Abstract][Full Text] [Related]
39. The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.
Majumdar S; Diamandis EP
Br J Cancer; 1999 Mar; 79(9-10):1594-602. PubMed ID: 10188912
[TBL] [Abstract][Full Text] [Related]
40. An 8q24 gene desert variant associated with prostate cancer risk confers differential in vivo activity to a MYC enhancer.
Wasserman NF; Aneas I; Nobrega MA
Genome Res; 2010 Sep; 20(9):1191-7. PubMed ID: 20627891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
